Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evolus Inc.

9.10
-0.5200-5.41%
Post-market: 9.06-0.0400-0.44%18:38 EDT
Volume:687.59K
Turnover:6.32M
Market Cap:586.73M
PE:-10.24
High:9.57
Open:9.57
Low:9.09
Close:9.62
Loading ...

US FDA approves Evolus' anti-wrinkle gels

Reuters
·
14 Feb

Evolus announces FDA approval of Evolysse products

TIPRANKS
·
14 Feb

Evolus Inc - Evolysse Sculpt to Launch in 2026, Evolysse Lips in 2027

THOMSON REUTERS
·
14 Feb

Evolus Announces FDA Approval of Evolysse™ Form and Evolysse™ Smooth Injectable Hyaluronic Acid Gels

THOMSON REUTERS
·
14 Feb

Evolus trading halted, news pending

TIPRANKS
·
14 Feb

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 Feb

Evolus price target raised to $22 from $20 at Barclays

TIPRANKS
·
27 Jan

Barclays Sticks to Their Buy Rating for Evolus (EOLS)

TIPRANKS
·
27 Jan

Stock Track | Evolus Inc. Stock Soars 5.12% as Q4 Results Impress, Driving Optimism for Growth

Stock Track
·
23 Jan

Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains?

Zacks
·
22 Jan

Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS)

TIPRANKS
·
22 Jan

Evolus Price Target Maintained With a $22.00/Share by Needham

Dow Jones
·
22 Jan

BUZZ-Evolus rises after preliminary Q4 revenue beats estimates

Reuters
·
21 Jan

Evolus Reports Q4 Preliminary Net Revenue; Shares Rise Pre-Bell

MT Newswires Live
·
21 Jan

Evolus Shares Rise on Jump in Revenue

Dow Jones
·
21 Jan

Evolus Projects FDA Nod For Evolysse Gels Within 90 Days, Eyes Q2 2025 U.S. Rollout; Reports $79M Q4 2024 Revenue, FY24 Revenue $266.3M; Expects $345M-$355M Net Revenue And $230M-$240M Non-GAAP Expenses For 2025; Plans 8-10% Revenue From Evolysse, Estyme Gels

Benzinga
·
21 Jan

Evolus Inc: Preliminary Unaudited Net Revenue of $79.0 Mln for Q4 2024

THOMSON REUTERS
·
21 Jan

Evolus Inc: Maintains Projection for FY2025 Profitability

THOMSON REUTERS
·
21 Jan

Evolus Outlook FY Sales USD 345-355 Million

THOMSON REUTERS
·
21 Jan